Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Still a Buy?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) shares gapped up prior to trading on Friday . The stock had previously closed at $9.26, but opened at $9.73. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.01, with a volume of 704 shares traded.

Analysts Set New Price Targets

Several analysts have recently weighed in on SGIOY shares. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Tuesday, July 14th. Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Finally, The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR currently has an average rating of “Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 2.7%

The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.00. The stock has a market capitalization of $15.83 billion, a P/E ratio of 9.30, a PEG ratio of 3.32 and a beta of 0.08. The stock’s fifty day moving average is $9.02 and its two-hundred day moving average is $9.52.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.18. The company had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 16.13% and a net margin of 46.67%. As a group, research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, the company has built its business around drug discovery and has a particular focus on infectious diseases, including antiviral and antibacterial treatments.

Shionogi’s products include Xofluza (baloxavir marboxil), an oral treatment for influenza, and Fetcroja (cefiderocol), an antibiotic used for certain difficult-to-treat bacterial infections.